Over The Counter Stocks

[PRAYFORME]

OWCP!!! a must have and this is why.

$$OWCP$$ DD PACKAGE:

Authorized Shares 500,000,000 a/o Sep 23, 2016
Outstanding Shares 135,305,475 a/o Oct 18, 2016

OWC Pharmaceutical Research Corp Completes Development of Its Medical Cannabis Sublingual Tablet

OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that it has completed the development of a proprietary, cannabinoid-enriched sublingual tablet (the "Tablet") for the administration of medical cannabis.

Mr. Turner went on to say, "We are already in discussion with the Ministry of Health here in Israel, and we have been solicited by a number of licensee candidates looking to bring the technology to the States. Of course we will have to pursue the US market on a state by state basis, as regulations allow."

TEVA TRIED TO BUY OWCP PATENTS LAST YEAR WORTH A WHOLE LOT MORE WITH RECENT DEVELOPMENTS

TEVA CURRENTLY TRADING AT $40.1Bill MARKET CAP
Teva, according to a report by The Marker, has made an offer for One World Cannabis (OWC) to purchase the rights to the company’s patents. One World is developing treatments using the compound in cannabis to treat chronic pain, multiple myeloma and other conditions.
http://www.jewishpress.com/news/breaking-news/teva-pharmaceuticals-thinks-its-high-time-for-medical-marijuana/2015/07/21/


On October 18, 2016, the Registrant had 135,305,475 shares of common stock outstanding.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11644926

Item 8.01 Other Events.
The Registrant is reporting in this Form 8-K that effective on October 3, 2016, the Registrant has no convertible debt outstanding whatsoever.

Item 1.02 Termination of a Material Definitive Agreement.

On September 28, 2016, One World Cannabis Ltd. ("OWC Ltd"), a wholly-owned Israeli subsidiary of OWC Pharmaceutical Research Corp. (the "Registrant"), entered into a loan agreement with Medmar LLC , organized under the laws of the State of Maryland ("Medmar"), effective as of September 22, 2016 pursuant to which Medmar has agreed to loan OCW Ltd a total of $300,000 on a non-interest bearing basis, with no conversion rights. Medmar agreed to fund the Loan in six equal installments of $50,000 each. To date, OWC Ltd. has received $100,000 of the total Medmar loan commitment.

As a result of the Medmar loan, the Registrant, effective October 14, 2016, served notice on Kodiak Capital Group, LLC ("Kodiak") that it was: (i) terminating the Equity Purchase Agreement between the Registrant and Kodiak dated December 17, 2015 and amended on May 17, 2016; and (ii) withdrawing the pending registration statement on Form S-1 that had been filed with the SEC on June 16, 2016.

Item 8.01 Other Events.
The Registrant is reporting in this Form 8-K that effective on October 3, 2016, the Registrant has no convertible debt outstanding whatsoever.

8k: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11636306

MEANS PPS CAN ONLY GO UP NO DOWNWARD PRESSURE ON PPS. OWCP CURRENT MARKET CAP IS UNDERVALUED WHEN COMPARED AGAINST ITS COMPETITORS

OWC Pharmaceutical Research Corp to Initiate Efficacy Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis
WC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it is starting the final phase for testing the efficacy of its own developed topical crème compound for the treatment of psoriasis and related skin conditions.

PR:https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-initiate-120000414.html

See below NO MORE TOXICS OWCP got $300k NON INTEREST BEARING LOAN WITH NO CONVERSION RIGHTS TO FUND OPERATIONS


OWCP an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it signed an agreement for $300,000 with Medmar LLC ("Medmar").

According to the terms of the agreement:

The funds will be allocated to complete the development of the Company's proprietary psoriasis cream;

Medmar will have exclusive right to manufacture, produce, publicize, promote and market OWC's Licensed Products in any state in the U.S;

The loan is non-interest bearing and will be repaid from royalties generated by the sale of OWC licensed products.

More details:
Medmar has agreed to loan OCW Ltd a total of $300,000 (the “Loan”) on a non-interest bearing basis, with no conversion rights. Medmar will fund the Loan in six equal installments of $50,000 each, as follows: (i) 1st installment was released to OWC Ltd on September 22, 2016; (ii) 2nd installment on October 1, 2016; (iii) 3rd installment on November 1, 2016; (iv) 4th installment on December 1, 2016; (v) 5th installment on January 1, 2017; and (vi) 6th installment on February 1, 2017. The Loan, as noted above, bears no interest, is not convertible, is due in 36 months from the Effective Date, and repayment shall be made only by the set off of royalties payable by Medmar to OWC Ltd.

PR:https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-signs-120000921.html

8k: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11614519


!!OWC Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!

There are many different companies active in the medical marijuana industry, but few of them are conducting clinical research trials in accord with the Helsinki Committee Institutional Review Board protocols. Most investors are familiar with GW Pharmaceuticals plc (NASDAQ: GWPH) and its Sativex® cannabinoid medicine for the treatment of multiple sclerosis symptoms and cancer pain indications, but OWC Pharmaceutical Research Corp. (OTCQB: OWCP) is a lesser known company operating in the burgeoning industry.

Based in Israel, an international tech and biotech hub, and the epicenter of medical cannabis research, the OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines. The team is also working on several proprietary drug delivery mechanisms designed to provide consistent and reliable cannabinoid doses to patients more efficiently than smoking or consuming marijuana edibles.

Full Article below Please watch the interview: http://www.baystreet.ca/viewarticle.aspx?id=437873

99% of all CANNABIS RESEARCH IS BEING DONE IN ISREAL, OWCP IS AT THE EPICENTER OF THIS WORK

OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.

Big Money to be made here next GWPH.

Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.

Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.

Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has started the final phase of Safety testing protocol was designed to corroborate that the cream is safe for application to the skin. OWCP is also preparing to initiate in parallel Efficacy Testing using MatTek Corporation patented EpiDerm™ system, an in-vitro testing technology for dermal toxicologists. This protocol will seek to prove the effectiveness of the formulation in treating psoriasis on human skin tissue.

Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.